Tremelimumab
- Generic Name
- Tremelimumab
- Brand Names
- Imjudo, Tremelimumab AstraZeneca
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 745013-59-6
- Unique Ingredient Identifier
- QEN1X95CIX
- Background
Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces tu...
- Indication
Tremelimumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma in combination with durvalumab. It is also indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC)
- Associated Therapies
- -
Tremelimumab With Chemoembolization or Ablation for Liver Cancer
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 61
- Registration Number
- NCT01853618
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2013-04-30
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 571
- Registration Number
- NCT01843374
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma
- First Posted Date
- 2012-08-02
- Last Posted Date
- 2012-08-02
- Lead Sponsor
- Azienda Ospedaliera Universitaria Senese
- Target Recruit Count
- 29
- Registration Number
- NCT01655888
- Locations
- 🇮🇹
Medical Oncology and Immunotherapy Unit, University Hospital of Siena, Siena, Italy
A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma
- First Posted Date
- 2012-07-25
- Last Posted Date
- 2012-07-25
- Lead Sponsor
- Azienda Ospedaliera Universitaria Senese
- Target Recruit Count
- 29
- Registration Number
- NCT01649024
- Locations
- 🇮🇹
Medical Oncology and Immunotherapy Unit, University Hospital of Siena, Siena, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.